Recursion Pharmaceuticals Inc (RXRX)
7.50
-0.08
(-0.99%)
USD |
NASDAQ |
Jun 28, 16:00
7.55
+0.05
(+0.67%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (Annual): 241.23M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 241.23M |
| December 31, 2022 | 155.70M |
| December 31, 2021 | 135.27M |
| Date | Value |
|---|---|
| December 31, 2020 | 63.32M |
| December 31, 2019 | 45.81M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
45.81M
Minimum
2019
241.23M
Maximum
2023
128.26M
Average
135.27M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 63.81M |
| Tonix Pharmaceuticals Holding Corp | 86.66M |
| Actinium Pharmaceuticals Inc | 38.67M |
| Macrogenics Inc | 166.58M |
| Marinus Pharmaceuticals Inc | 99.39M |